Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-3894

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-3894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Losartan Potassium 25 mg film-coated tablets label displaying the prescription drug status, NDC 70518-3894-00, and packaging quantity of 90 tablets. The label includes storage instructions, manufacturer information for Camber Pharma, Inc., and repackager contact details for RemedyRepack Inc., Indiana, PA. The design features a purple color theme with a barcode and a QR code.*

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with primary endpoints over a 60-month study period between Losartan potassium and Atenolol. The graph shows a steady increase over time for both medications, with an adjusted risk reduction of 13% for Losartan potassium (p=0.021). The x-axis represents study months and the y-axis shows percentage of patients with primary endpoints.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal strokes over study months between two treatments: Atenolol (dashed line) and Losartan Potassium (solid line). The graph shows a lower cumulative incidence of stroke for Losartan Potassium, with an indicated adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

Figure 3 presents a forest plot showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. It displays event rates and hazard ratios with confidence intervals for primary composite outcomes and stroke (fatal/non-fatal) across age, gender, race, ISH, diabetes, and history of cardiovascular disease subgroups.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph showing the percent of patients with events over 48 months comparing Losartan potassium with placebo. The y-axis represents the percentage of patients, and the x-axis shows time in months. The graph includes a risk reduction percentage of 16.1% and a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium showing its molecular framework including phenyl rings, tetrazole ring, and other characteristic groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.